Nancy Schlichting - Dec 3, 2021 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Director
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
Dec 3, 2021
Transactions value $
$0
Form type
4
Date filed
12/7/2021, 04:26 PM
Previous filing
Nov 23, 2021
Next filing
Dec 14, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Stock Option (Right to Buy) Award +110K 110K Dec 3, 2021 Common Stock 110K $1.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 33% of the shares underlying the option vested or shall vest on December 1, 2021, an additional 33% of the shares vested or shall vest on December 1, 2022, and an additional 34% of the shares vested or shall vest on December 1, 2023.
F2 Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 75,000 shares of common stock of Private Pear for $1.77 per share.